Previous 10 | Next 10 |
Even as Alnylam ( ALNY ) works toward its second commercial drug filing, questions remain about the safety and efficacy of givosiran, not to mention the platform as a whole. But with good full Phase III data on givosiran and encouraging open-label extension data on lumasiran over the last fe...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Editor's note: Seeking Alpha is proud to welcome Timothy Sargis as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » RNA interf...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive offic...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) presents updated data from its ongoing PHYOX 1 Phase 1 trial evaluating DCR-PHXC, a GalXC product candidate. More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
—PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50 th Annual Meeting— —Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Rebecca Peterson - Head of Corporate Communications Douglas Fambrough - President and Chief Executive Officer Jack Green - Chief Financial Officer Ral...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) announces key events for 2019: More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...